{"groups":[{"description":"Schedule 1:LACP:study start to 06-Nov-2022:Lazertinib 240 milligrams(mg) orally daily along with amivantamab and chemotherapy (carboplatin and pemetrexed). Amivantamab 1400 mg (1750 mg if body weight\\>= 80 kilograms\\[kg\\]) intravenous(IV) infusion on Cycle 1 Days 1/2, 8 and 15 and Cycle 2 Day 1 and then 1750 mg (2100 mg if body weight \\>=80 kg) on Day 1 of each 21-day cycle, starting at cycle 3. Participants received chemotherapy:pemetrexed 500 milligrams per meter square(mg/m\\^2) IV infusion on Day 1 of each 21-day cycle, along with carboplatin area under concentration-time curve of 5 (AUC 5) IV infusion on Day 1 for up to 4 cycles and then as maintenance monotherapy until disease progression(DP). Schedule 2:ACP-L:07-Nov-2022 to study end:Amivantamab 1400 mg (1750 mg if body weight\\>=80 kg) IV infusion on Cycle 1 Days 1/2, 8 and 15 and Cycle 2 Day 1 and then 1750 mg (2100 mg if body weight \\>=80 kg) on Day 1 of each 21-day cycle, starting at cycle 3. Participants also received chemotherapy:pemetrexed 500 mg/m\\^2 IV infusion on Day 1 of each 21-day cycle, along with carboplatin AUC 5 IV infusion on Day 1 for up to 4 cycles and then as maintenance monotherapy until DP. Lazertinib was administered 240 mg orally, once daily starting Cycle 5 Day 1 or sooner if carboplatin was discontinued earlier. In both schedules, Lazertinib, amivantamab and pemetrexed:continued until DP, participant withdrawal, adverse event, investigator's decision/initiation of new systemic anti-cancer treatment.","id":"FG000","title":"Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L)"},{"description":"Participants received chemotherapy with pemetrexed 500 mg/m\\^2 IV infusion on Day 1 of each 21-day cycle, in combination with carboplatin area under the concentration-time curve of 5 mg/mL per minute (AUC 5) was administered as an IV infusion on Day 1, for up to 4 cycles, and then as maintenance monotherapy until disease progression, participant consent withdrawal, adverse event, investigator's decision, or initiation of new systemic anti-cancer treatment.","id":"FG001","title":"Main Study: Arm B: Carboplatin + Pemetrexed (CP)"},{"description":"Participants received amivantamab 1400 mg (1750 mg if body weight is \\>= 80 kg) by IV infusion once weekly starting from Cycle 1 Days 1/2, 8, and 15, and Cycle 2 Day 1, then 1750 mg (2100 mg if body weight is \\>=80 kg) on Day 1 of each 21-day cycle, starting with Cycle 3. Participants also received chemotherapy with pemetrexed 500 mg/m\\^2 IV infusion on Day 1 of each 21-day cycle, in combination with carboplatin area under the concentration-time curve of 5 mg/mL per minute (AUC 5) was administered as an IV infusion on Day 1, for up to 4 cycles. Amivantamab and pemetrexed treatments were to be continued until disease progression, participant consent withdrawal, adverse event, investigator's decision, or initiation of new systemic anti-cancer treatment.","id":"FG002","title":"Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP)"},{"description":"In Arm A2, participants received amivantamab 1400 mg (1750 mg if body weight\\>=80 kg) IV infusion once weekly from Cycle 1 Days 1/2, 8, and 15, and Cycle 2 Day 1, and then 1750 mg (2100 mg if body weight \\>=80 kg) on Day 1 of each 21-day cycle, starting at cycle 3. Participants also received chemotherapy: pemetrexed 500 mg/m\\^2 IV infusion on Day 1 of each 21-day cycle, in combination with carboplatin area under concentration-time curve of 5 mg/mL per minute (AUC 5) IV infusion administered on Day 1 for up to 4 cycles. Lazertinib was administered 240 mg orally, once daily starting Cycle 5 Day 1 or sooner if carboplatin was discontinued earlier. Amivantamab, pemetrexed and lazertinib were to be continued until disease progression (DP), participant withdrawal, adverse event (AE), investigator's decision or initiation of new systemic anti-cancer treatment. In Arm C2, participants received amivantamab 1400 mg (1750 mg if body weight \\>=80 kg) IV infusion once weekly from Cycle 1 Days 1/2, 8, and 15, and Cycle 2 Day 1, then 1750 mg (2100 mg if body weight is \\>=80 kg) on Day 1 of each 21-day cycle, starting with Cycle 3. Participants also received chemotherapy: pemetrexed 500 mg/m\\^2 IV infusion on Day 1 of each 21-day cycle, in combination with carboplatin AUC 5 IV infusion was administered on Day 1, for up to 4 cycles. Amivantamab and pemetrexed were to be continued until DP, participant withdrawal, AE, investigator's decision or initiation of new systemic anti-cancer treatment.","id":"FG003","title":"Extension Cohort: All Participants (Arm A2 [ACP-L] + C2 [ACP])"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"29"},{"groupId":"FG002","numSubjects":"6"},{"groupId":"FG003","numSubjects":"0"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"186"},{"groupId":"FG001","numSubjects":"169"},{"groupId":"FG002","numSubjects":"99"},{"groupId":"FG003","numSubjects":"119"}],"type":"Study participation ongoing"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"263"},{"groupId":"FG001","numSubjects":"263"},{"groupId":"FG002","numSubjects":"131"},{"groupId":"FG003","numSubjects":"119"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"263"},{"groupId":"FG001","numSubjects":"243"},{"groupId":"FG002","numSubjects":"130"},{"groupId":"FG003","numSubjects":"119"}],"type":"Treated (Safety Analysis Set)"},{"achievements":[{"groupId":"FG000","numSubjects":"67"},{"groupId":"FG001","numSubjects":"65"},{"groupId":"FG002","numSubjects":"26"},{"groupId":"FG003","numSubjects":"0"}],"comment":"As per protocol, participants who died were also considered as completed","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"196"},{"groupId":"FG001","numSubjects":"198"},{"groupId":"FG002","numSubjects":"105"},{"groupId":"FG003","numSubjects":"119"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"At the time of PCD, extension cohort enrollment was still ongoing. As per protocol, extension cohort analysis was not included as part of main study primary analysis. Currently no information other than total count of participants for extension cohort is available and for reporting purpose extension cohort arms (A2 and C2) have been combined in the table. Results of extension cohort will be reported later, upon completion of analysis, at which point arms A2 and C2 details will be reported.","recruitmentDetails":"A total of 657 participants were enrolled in the main study. During the study, a separate open-label randomized extension cohort was added. A total of 119 participants were enrolled into the extension cohort. Main study results are alone reported for primary completion date (PCD; 10-July-2023)."}